U69-CART-Cells For R/R T-ALL

This study is testing a new CAR-T cell therapy — called U69-CART — designed to treat relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma (T-ALL/LBL), a rare and difficult-to-treat blood cancer. The therapy uses the patient's own immune cells, genetically re-engineered to seek and destroy cancer cells that carry a protein called CCR9. **You may be eligible if...** - You are 15–75 years old - You have confirmed relapsed or refractory T-ALL or T-LBL with no remaining standard treatment options - Your cancer cells are confirmed to express the CCR9 protein - You are in reasonably good physical health (ECOG 0–2) with expected survival over 3 months - Your organs (heart, liver, kidneys) are functioning at acceptable levels **You may NOT be eligible if...** - You have had prior CAR-T therapy targeting CCR9 - You have leukemia in the brain causing symptoms - You have active hepatitis B, C, HIV, CMV, or EBV infections - You have had another cancer within 3 years (with some exceptions) - You have had a stem cell transplant from another donor within 12 months Talk to your doctor to see if this trial is right for you.